Last reviewed · How we verify
ExPEC4V
At a glance
| Generic name | ExPEC4V |
|---|---|
| Also known as | JNJ-63871860 |
| Sponsor | Janssen Pharmaceutical K.K. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health (PHASE1, PHASE2)
- A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860 (PHASE2)
- A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ExPEC4V CI brief — competitive landscape report
- ExPEC4V updates RSS · CI watch RSS
- Janssen Pharmaceutical K.K. portfolio CI